Chartis System

The Chartis system is a pulmonary diagnostic tool that allows physicians to identify which patients are appropriate for the Zephyr valve procedure.

  • Provides precise flow and pressure readings for specific lobes in the lungs to assess collateral ventilation
  • Over 70% of treatment responders are correctly identified using the Chartis system1

1 Hopkinson NS et al. (2011) Eur Respir J

 

How It Works

Image of inflated Chartis Baloon Catheter
The Chartis balloon catheter is inserted through a bronchoscope to the target airway, and the balloon is inflated to block flow to the target region.
Image of Chartis System
The system calculates airway resistance and measures CV in isolated lobes in the lung. The Chartis console displays expiratory air flow (orange), pressure (blue), and resistance measurements.

 

Chartis System

Item Number Description
CHR-CO-100 Chartis Pulmonary Assessment System – Console
CHR-CA-12.0 Chartis Pulmonary Assessment System – Catheter
CHR-CA-12.0-XL Chartis Pulmonary Assessment System – Catheter XL

Note: The Chartis System consists of a disposable balloon catheter and console.

Collateral ventilation can limit the effectiveness of endobronchial LVR therapy1,2

Using the Chartis system to accurately assess collateral ventilation (CV) within the targeted treatment area, physicians can identify which patients are appropriate for the Zephyr valve therapy.

Image of Collateral ventilation

Collateral ventilation (CV+)

Expiratory airflow persists over time, indicating the presence of collateral airflow from adjacent lung compartments.

Image of no collateral ventilation

No collateral ventilation (CV-)

Expiratory airflow in the lung compartment is reduced over several breathing cycles, indicating little to no collateral airflow from adjacent lung compartments.

1 Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.
2 Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.